C12N 2760/18511
Pneumovirus
Official title: Pneumovirus, e.g. human respiratory syncytial virus
C12N2760/18511 (Pneumovirus) appears on 653 US grants and 934 published applications in this corpus.
Search patents in C12N- Granted patents
- 653
- Published applications
- 934
- Assignees
- 387
- Inventors
- 1,492
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 14 | 0 |
| 1999 | 16 | 0 |
| 2000 | 28 | 0 |
| 2001 | 16 | 1 |
| 2002 | 16 | 12 |
| 2003 | 11 | 15 |
| 2004 | 15 | 26 |
| 2005 | 6 | 28 |
| 2006 | 4 | 15 |
| 2007 | 8 | 18 |
| 2008 | 8 | 19 |
| 2009 | 16 | 20 |
| 2010 | 15 | 36 |
| 2011 | 5 | 25 |
| 2012 | 5 | 29 |
| 2013 | 14 | 30 |
| 2014 | 19 | 44 |
| 2015 | 26 | 39 |
| 2016 | 28 | 44 |
| 2017 | 31 | 38 |
| 2018 | 29 | 37 |
| 2019 | 36 | 55 |
| 2020 | 36 | 54 |
| 2021 | 36 | 53 |
| 2022 | 44 | 71 |
| 2023 | 53 | 78 |
| 2024 | 40 | 68 |
| 2025 | 41 | 43 |
| 2026 | 18 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18534Use of virus or viral component as vaccineIndexing code478
- C12N 2760/18522New viral proteins or individual genes, new structural or functional aspects ofIndexing code364
- C12N 2760/18571Demonstrated in vivo effectIndexing code84
- C12N 2760/18561Methods of inactivation or attenuationIndexing code70
- C12N 2760/18523Virus like particles [vlp]Indexing code34
- C12N 2760/18541Use of virus, viral particle or viral elements as a vectorIndexing code34
- C12N 2760/18521Viruses as suchIndexing code32
- C12N 2760/18551Methods of production or purification of viral materialIndexing code29
All 12 subgroupsShow fewer
Recent patents
- Cell culture process for producing RSV F protein15 Sep 2026US 12,734,231 B2Pfizer Inc.
- Conformationally stabilized RSV pre-fusion F proteins11 Aug 2026US 12,703,721 B2
- Respiratory syncytial virus (RSV) polyanhydride nanoparticle vaccine14 Jul 2026US 12,678,410 B2University of Iowa Research Foundation
- Use of BCG immunogenic formulation expressing a respiratory syncitial virus protein against hMPV30 Jun 2026US 12,667,611 B2Pontificia Universidad Catolica De Chile
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- Immunogenic compositions against influenza and rsv17 Sep 2026US 2026/0273040 A1Pfizer Inc.
- Rsv vaccine composition, method and use thereof10 Sep 2026US 2026/0263581 A1Sichuan Clover Biopharmaceuticals, Inc.
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Antigenic Multimeric Respiratory Syncytial Virus Polypeptides10 Sep 2026US 2026/0265309 A1Sanofi
- Methods of Isolating Poxviruses from Avian Cell Cultures27 Aug 2026US 2026/0248906 A1Bavarian Nordic A/S
Most cited
By later US patents
- Cationic lipids and the use thereof249US 5,830,430 AImaRx Pharmaceutical Corp. · 1998
- Cationic lipids and the use thereof138US 6,056,938 AImarx Pharaceutical Corp. · 2000
- Prevention and treatment of respiratory tract disease115US 5,716,821 AThe UAB Research Foundation · 1998
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof110US 5,811,524 AIDEC Pharmaceuticals Corporation · 1998